Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
The latest announcement is out from RemeGen Co. Ltd. Class H ( (HK:9995) ).
RemeGen Co., Ltd. held its first extraordinary general meeting of 2025, where the shareholders approved the appointment of Mr. Huang Guobin as an independent non-executive director. This change in the board’s composition also led to Mr. Huang’s appointment as the chairman of the Nomination Committee and a member of the Strategy Committee, following the resignation of Dr. Ma Lan. The meeting saw significant shareholder participation, with over 39% of shares represented, reflecting active engagement in the company’s governance.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China. It operates within the pharmaceutical industry, focusing on the research, development, and commercialization of innovative biologics for the treatment of cancer, autoimmune diseases, and ophthalmic disorders.
YTD Price Performance: -13.19%
Average Trading Volume: 2,516,602
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$12.06B
See more data about 9995 stock on TipRanks’ Stock Analysis page.
